COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies

Coronavirus-triggered pulmonary and systemic disease, i.e. systemic inflammatory response to virally triggered lung injury, named COVID-19, and ongoing discussions on refining immunomodulation in COVID-19 without COX2 inhibition prompted us to search the related literature to show a potential target...

Descripción completa

Detalles Bibliográficos
Autores principales: Baghaki, Semih, Yalcin, Can Ege, Baghaki, Hayriye Sema, Aydin, Servet Yekta, Daghan, Basak, Yavuz, Ersin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525269/
https://www.ncbi.nlm.nih.gov/pubmed/33007455
http://dx.doi.org/10.1016/j.ijid.2020.09.1466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525269/
https://www.ncbi.nlm.nih.gov/pubmed/33007455
http://dx.doi.org/10.1016/j.ijid.2020.09.1466

Ejemplares similares